Medicare payments for dermatology procedures have fallen 29%, according to a Medscape report — one of the steepest reimbursement declines visible across medical specialties and a figure that puts direct financial pressure on dermatology practices reliant on procedural revenue.

The 29% drop matters because dermatology sits at the intersection of evaluation-driven medical care and high-volume procedural work — skin biopsies, excisions, destruction of premalignant and malignant lesions, and cosmetic-adjacent services that Medicare covers when medically indicated. When payment per procedure falls by nearly a third, practices must either increase volume, shift payer mix, or absorb margin erosion on the services that anchor skin-cancer surveillance and treatment.

Why a 29% cut hits dermatology practices hard

Dermatology practices typically run on thin administrative overhead compared with hospital-based specialties. A single physician often performs dozens of Medicare-covered procedures per day — shave biopsies, punch biopsies, excisions staged by CPT code, cryotherapy for actinic keratoses. Each unit of work is reimbursed at a set fee-schedule rate, so a percentage decline in payment translates almost linearly into revenue decline at constant volume.

Unlike drug-based specialties that can negotiate rebates or shift to alternative agents, procedural dermatology has limited substitution options: the biopsy that confirms a melanoma diagnosis, staged by Breslow thickness and documented for AJCC staging, has no cheaper clinical equivalent. Practices cannot simply stop performing the procedures that drive skin-cancer detection.

The reported 29% figure also arrives amid a broader environment of Medicare fee-schedule conversion-factor cuts that Congress has addressed only with short-term patches, leaving specialty societies to lobby repeatedly for stability that never fully materializes.

What the decline means for access and coding strategy

For practice managers, a payment decline of this magnitude forces a reassessment of three levers:

• Coding accuracy. Capturing every legitimately billable element — lesion counts, anatomic sites, closure codes — becomes financially decisive when each unit reimburses less.
• Payer mix. Practices with heavy Medicare exposure face greater revenue compression than those balanced toward commercial contracts.
• Site-of-service decisions. Where a procedure is performed increasingly determines whether it remains economically viable.

Access is the downstream concern. If Medicare payment falls faster than practices can absorb, some will cap new Medicare patients or route procedures to higher-volume settings, potentially slowing the lesion-to-diagnosis pathway for skin-cancer patients — the cohort where diagnostic delay carries the clearest clinical cost.

The road ahead

The Medscape figure crystallizes what dermatology societies have warned about for years: procedural reimbursement is eroding while the clinical demand for skin-cancer surveillance and inflammatory-disease care keeps rising. Watch for specialty-society responses, proposed fee-schedule updates, and any legislative fix to the conversion factor in upcoming Medicare rulemaking cycles, each of which will determine whether the 29% decline marks a floor or a waypoint.